Biogen and UCB Reports Results of Dapirolizumab Pegol (DZP) in A P-IIb study for Systemic Lupus Erythematosus (SLE)

 Biogen and UCB Reports Results of Dapirolizumab Pegol (DZP) in A P-IIb study for Systemic Lupus Erythematosus (SLE)

UCB Reports Improved Results of Extended P-IIb BE ACTIVE study for Bimekizumab in Patients with Psoriatic Arthritis (PsA) Patients

Shots:

  • The A P-IIb study involves assessing of dapirolizumab pegol vs PBO in adults with moderate-to-severe SLE despite receiving SoC treatment, evaluating safety and efficacy
  • The study demonstrated unmet 1EP @24 wks. on the BICLA and showed improvements in majority of clinical endpoints, with safety and tolerability
  • Dapirolizumab pegol is an anti-CD40L pegylated Fab jointly developed by UCB &Biogen indicated in SLE. Additionally, Biogen & UCB plans to evaluate the above results

Click here to read full press release/ article | Ref: Biogen | Image:  Logos Discovery Engine

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post